Evaluation of Easym, a Clonotypic Mass Spectrometry Assay, and Euroflow Minimal Residual Disease Assessment in Multiple Myeloma

被引：0
|
作者：
Zhao, Jessie [1 ,2 ]
Khong, Tiffany T. [1 ,2 ]
Gorniak, Malgorzata [3 ]
Khaled, Abir [4 ]
McDonald, Zac [4 ]
Reynolds, John [1 ,2 ]
Wong, Daniel [1 ,2 ]
Bingham, Nicholas [1 ,2 ]
Johnston, Anna M. [5 ]
Motorna, Olga [6 ]
Murphy, Nicholas E. [5 ]
Quach, Hang [7 ]
Yang, Liqiang [4 ]
Spencer, Andrew [1 ,2 ]
机构：
[1] Alfred Hosp, Dept Malignant Haematol & Stem Cell Transplantat, Melbourne, Vic, Australia
[2] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia
[3] Alfred Hosp, Alfred Pathol, Melbourne, Vic, Australia
[4] Rapid Novor, Kitchener, ON, Canada
[5] Royal Hobart Hosp, Hobart, Tas, Australia
[6] Eastern Hlth, Melbourne, Vic, Australia
[7] St Vincents Hosp Melbourne, East Melbourne, Australia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179742
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Nishihori, Taiga
    Song, Jinming
    Shain, Kenneth H.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (02) : 118 - 126
  • [22] Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Taiga Nishihori
    Jinming Song
    Kenneth H. Shain
    Current Hematologic Malignancy Reports, 2016, 11 : 118 - 126
  • [23] Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)
    Yoroidaka, Takeshi
    Takamatsu, Hiroyuki
    Yamashita, Takeshi
    Murata, Ryoichi
    Yoshihara, Kyoko
    Yoshihara, Satoshi
    Ueda, Mikio
    Nakao, Shinji
    Matsue, Kosei
    BLOOD, 2019, 134
  • [24] Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
    Charalampous, Charalampos
    Kourelis, Taxiarchis
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [25] The role of minimal residual disease evaluation for patients with multiple myeloma
    Eun, Yoon Sang
    Kim, Hyun-Young
    Cho, Duck
    Kim, Seok Jin
    Kim, Kihyun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S80 - S80
  • [26] Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma
    Tan, Joanne L. C.
    Das, Tongted
    Kliman, David
    Muirhead, Jenny
    Gorniak, Malgorzata
    Kalff, Anna
    Walker, Patricia
    Spencer, Andrew
    BONE MARROW TRANSPLANTATION, 2021, 56 (05) : 1116 - 1125
  • [27] Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma
    Joanne L. C. Tan
    Tongted Das
    David Kliman
    Jenny Muirhead
    Malgorzata Gorniak
    Anna Kalff
    Patricia Walker
    Andrew Spencer
    Bone Marrow Transplantation, 2021, 56 : 1116 - 1125
  • [28] Minimal Residual Disease Monitoring By Targeted Mass Spectrometry Allows Early Relapse Detection in Multiple Myeloma
    Noori, Somayya
    Wijnands, Charissa
    Langerhorst, Pieter
    Nadal, Simon
    Bonifay, Vincent
    Stingl, Christoph
    Touzeau, Cyrille
    Luider, Theo
    Dejoie, Thomas
    Jacobs, Johannes
    Vanduijn, Martijn
    BLOOD, 2022, 140 : 2349 - 2350
  • [29] Minimal Residual Disease in Multiple Myeloma
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2523 - 2526
  • [30] Minimal residual disease for multiple myeloma
    Avet-Loiseau, Herve
    Corre, Jill
    HEMATOLOGIE, 2019, 25 : 36 - 39
12345